Evidence map›Paper›PMID 40615384›Full record

ArticleNPJ vaccines2025

Hamsters immunized with formalin-inactivated SARS-CoV-2 develop accelerated lung histopathological lesions and Th2-biased response following infection.

Rineke de Jong, Sandra Vreman, Katrin E Wiese, Nora M Gerhards, Kevin R Bewley, Yper Hall, Francisco Javier Salguero, Miles Carroll, Rik L de Swart, Jose L Gonzales and 1 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rineke de JongWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands. rineke.jong@wur.nl.
Sandra VremanWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Katrin E WieseWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Nora M GerhardsWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Kevin R BewleyUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, UK.
Yper HallUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, UK.
Francisco Javier SalgueroUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, UK.
Miles CarrollCentre for Human Genetics and the Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Rik L de SwartWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Jose L GonzalesWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands.
Nadia OreshkovaWageningen Bioveterinary Research, Wageningen University and Research, Lelystad, The Netherlands. Nadia.oreshkova@wur.nl.

Funding

Coalition for Epidemic Preparedness Innovations NA
6 · The paper itself

Abstract

One of the concerns regarding vaccine safety during the COVID-19 pandemic was the potential manifestation of vaccine-associated enhancement of disease (VAED) upon SARS-CoV-2 infection. To investigate the suitability of the Syrian hamster model to test for VAED, we immunized animals with an experimental formaldehyde-inactivated, alum-adjuvanted SARS-CoV-2 vaccine preparation. In two independent experiments, challenge infection did not result in an enhancement of the clinical disease in vaccinated animals compared with mock-vaccinated animals. However, at early timepoints (2-5 days) post-challenge, lung histopathology progressed faster and was more prominent in vaccinated hamsters and lung tissue showed elevated mRNA levels of IL-4 and IL-13. At later time points, cytokine responses and lung pathology were comparable between vaccinated and mock-vaccinated hamsters, underscoring the transient nature of the pathological aggravation. With this work we show that the Syrian hamster model can be used to assess possible vaccine safety considerations in a preclinical setting.

Identifiers

PMID40615384
PMCPMC12227699

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.